News | February 17, 2025
Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
No safety signals related to the vaccine candidate were identified
Offers affordable, high-quality solutions for diabetes care
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
Subscribe To Our Newsletter & Stay Updated
